• Thurs news: Novartis not joining weight loss race. Pharma marketing and climate change. Roche flu treatment trial. Cercle’s fund raise for women’s health. ICER looks at GSK COPD drugs. See more on our front page

Pfizer, in a rare COVID-19 setback, dumps Paxlovid's intravenous sibling in further...

Quote
cafead

cafead

Administrator
Staff member
  • cafead   Feb 09, 2022 at 10:22: AM
via Add Pfizer to the long list of victims of ACTIV-3. While the Big Pharma has enjoyed unparalleled success in COVID-19, it was unable to buck the trend in the National Institutes of Health (NIH) study of hospitalized patients and has stopped development of Paxlovid’s intravenous sibling PF-07304814.

article source
 

<



Similar threads

cafead
FDA reports rare complications with Pfizer COVID vaccine, updates J&amp;J safety info
Replies
0
Views
294
Pharma/Biotech Companies - In the News
cafead
cafead
cafead
Pfizer pivots from early-stage rare disease R&amp;D, shifting to external innovation and...
Replies
0
Views
665
Pharma/Biotech Companies - In the News
cafead
cafead
cafead
In warranty program, Pfizer will refund up to $50K for patients who discontinue use of rare...
Replies
0
Views
269
Pharma/Biotech Companies - In the News
cafead
cafead
cafead
Pfizer&#039;s Xalkori picks up FDA nod for rare ALK-positive tumors
Replies
0
Views
155
Pharma/Biotech Companies - In the News
cafead
cafead
cafead
Roche, Takeda and Pfizer notch top scores among rare disease patient advocacy groups
Replies
0
Views
179
Pharma/Biotech Companies - In the News
cafead
cafead
Top Bottom
Back
Quote